Article · Health news
NHS England begins offering mirvetuximab soravtansine for platinum-resistant ovarian cancer
NHS England has begun offering mirvetuximab soravtansine to hundreds of women with ovarian cancer that has stopped responding to platinum-based chemotherapy.
Key points
- NHS England announced on 4 June 2026 that mirvetuximab soravtansine would be available on the NHS from that day.
- It follows a recommendation by the National Institute for Health and Care Excellence (NICE).
- NHS England describes it as the first new addition to NHS treatment for this type of cancer in over 20 years.
What was announced
NHS England says hundreds of women with hard-to-treat ovarian cancer can have mirvetuximab soravtansine on the NHS from 4 June 2026. Following the NICE recommendation, it is for epithelial ovarian, peritoneal or fallopian tube cancer that has become resistant to platinum-based chemotherapy and whose tumours contain the folate receptor alpha (FR alpha) protein that the drug targets.
What it means
The drug combines a homing antibody with a cancer-killing medicine. NHS England says it may have more tolerable side effects than traditional chemotherapy.
More guides and news
- MHRA: venlafaxine and DAT scan results Health news · 27 October 2026
- NICE publishes osteoporosis risk guideline Health news · 29 July 2026
Educational content. This article summarises public guidance and announcements in plain English for education. It is not medical advice and it cannot say what is right for you: speak to a clinician about your own health, call NHS 111 if you are unsure what to do and 999 in an emergency.